Akebia Therapeutics, Inc. (AKBA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ: AKBA) common stock in the December 2018 transaction by which Keryx became a wholly-owned subsidiary of Akebia. Such shareholders are encouraged to obtain additional information and assist the investigation.   


The investigation concerns whether Akebia Therapeutics, Inc. failed to provide relevant information to Keryx shareholders in advance of the merger.


If you owned shares of Keryx Biopharmaceuticals, Inc. and received shares of Akebia Therapeutics, Inc. in the December 2018 merger, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.